SME Times is powered by   
Search News
Just in:   • Delhi Airport issues public health advisory amid Ebola concerns  • Portugal sees economic ties with India as key partnership for future: Joao Rui Ferreira  • PM Modi’s UAE visit strengthens India’s energy security amid rising Middle East tensions: Report  • India, Italy agree to expand bilateral trade to 20 billion euros by 2029  • India–Nordic Summit 2026 to help rewrite global tech governance rules 
Last updated: 27 Sep, 2014  

India Flag Amblem THMB Cabinet defers decision on relaxing FDI norms in pharma

fdi-retail.jpg
   Top Stories
» Delhi Airport issues public health advisory amid Ebola concerns
» Indian equity markets trade higher in early deals amid positive global cues
» Sensex, Nifty open lower amid weak global cues, geopolitical tensions
» PM Modi's Europe outreach brings tech, geopolitical gains for India
» India one of world’s most attractive destinations for investment, innovation: PM Modi
SME Times News Bureau | 29 Nov, 2013
The Cabinet Thursday deferred decision on relaxing FDI norms for the housing sector and reducing foreign investment limit to 49 percent in rare and critical areas of the pharma segment, reports media.

The decision on FDI in pharma and housing has been deferred, Information and Broadcasting Minister Manish Tewari said after the Cabinet meeting in New Delhi.

The Department of Industrial Policy and Promotion (DIPP) has proposed to reduce FDI cap from 100 per cent to 49 per cent in the "rare or critical pharma verticals".

Several departments, including the DIPP, have raised serious concerns over continuous acquisitions of Indian drug makers by global multinational firms.

According to sources, three categories have been proposed to define "rare or critical". It includes companies with five or more manufacturing units, and companies with 40 per cent or more market share irrespective of the total number of manufacturing facilities.

"If an entity manufactures multiple products, it will be treated as critical if either of the above two conditions are satisfied for at least one third of the products," said a source.

The DIPP has also proposed incorporating conditions for foreign firms like mandatory investment in R&D and non-compete clause in the shareholders pact.

India at present permits 100 per cent FDI in the pharma sector through automatic approval route in the new projects, but the foreign investment in existing pharma companies is allowed only through FIPB's approval.

Regarding FDI in the housing sector, DIPP has proposed relaxing FDI norms including easing conditions for exit before the three-year lock-in period. It has proposed easing conditions for exit of foreign players before the three-year lock-in period. 
 
Print the Page Add to Favorite
 
Share this on :
 

Please comment on this story:
 
Subject :
Message:
(Maximum 1500 characters)  Characters left 1500
Your name:
 

 
  Customs Exchange Rates
Currency Import Export
US Dollar
₹94.2
₹92.5
UK Pound
₹128.85
₹124.8
Euro
₹112.2
₹108.45
Japanese Yen ₹59.85 ₹58
As on 06 May, 2026
  Daily Poll
What is the biggest war impact on MSMEs?
 Export Disruption
 Raw Material Spike
 Freight Cost Surge
 Payment Delays
 Currency Volatility
 All
  Commented Stories
 
 
About Us  |   Advertise with Us  
  Useful Links  |   Terms and Conditions  |   Disclaimer  |   Contact Us  
Follow Us : Facebook Twitter